Medtronic has today announced that Linnea Burman will succeed Dan Volz as its senior vice president (SVP) and president of its Neurovascular business—part of the company’s Neuroscience portfolio.
In her new capacity, Burman will be responsible for portfolio strategy, product development, commercial execution and the overall financial performance of the Medtronic global business focused on stroke treatment. Burman will report to Brett Wall, executive VP and president of the Neuroscience portfolio at Medtronic.
Dan Volz will be stepping into a new role as SVP of global commercial transformation at Medtronic. In this newly established role, Volz will lead the company-wide effort to modernise and transform commercial strategies, and go-to-market approaches.
“Linnea is a strategic and visionary leader who maintains a customer-first mindset while building and developing high-performing teams,” said Wall. “Her strong record of success, deep MedTech industry knowledge, and previous experience in stroke, demonstrate her business acumen and underscore the commitment to making a meaningful impact on patient outcomes. I have the utmost confidence the Neurovascular business will continue to thrive under her leadership.”
Burman is described in a Medtronic press release as a transformational leader with more than 20 years of experience managing high-achieving global teams. Prior to her promotion to Neurovascular, Burman served as VP and general manager (GM) of enabling technologies within the Medtronic Cranial and Spinal Technologies (CST) business. She was integral to establishing CST, driving commercial growth strategies, innovative solutions, and a culture of collaboration, the release adds.
Burman has held many leadership positions throughout her tenure at Medtronic. Through the drug-delivery business, she played a pivotal role in elevating market development for a post-stroke spasticity indication. Burman also fostered close relationships with renowned stroke neurologists, influential stroke associations and dedicated patient advocacy groups.
“I’m continually inspired by Medtronic’s dedication to innovation and honoured to step into my new role in the Neurovascular business that has transformed the stroke treatment landscape unlike any other MedTech firm,” said Burman. “I look forward to working with my new team to build on our proven track record of advancing stroke care practices, fostering new partnerships within the neurovascular community, and developing effective therapies grounded in compelling clinical evidence.”
In addition to her business responsibilities, Burman is actively involved in leading inclusive and supportive professional networks. She is passionate about women in leadership positions, serving as an executive chair for the ASPIRE network, which champions the growth, development and success of women field employees at Medtronic, and is engaged in the Medtronic Women’s Network (MWN) too. While at CST, Burman founded the ET Enablers—a global employee group dedicated to enhancing two-way communication and collaboration.
